跳到主要內容

Manning Paul B 的 Form 4 申報

Verrica Pharmaceuticals Inc.(VRCA),2025/11/25 申報

申報編號
0001494695-25-000004
申報時間
2025/11/25
交易日
2025/11/25
申報延遲
當天
10b5-1 計畫
沒有勾選

這份申報列了 2 筆非衍生性交易、2 筆衍生性交易。公開市場買進合計 $1,749 萬。交易當天就申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Manning Paul BCIK 0001494695董事、持股 10% 以上大股東

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2025/11/25Common StockP買進取得+1,375,380$4.24+$5,831,611.23,958,189直接
2025/11/25Common StockP買進取得+2,750,762$4.24+$11,663,230.883,348,372間接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2025/11/25Common StockP買進取得+343,845–F8–343,845直接
2025/11/25Common StockP買進取得+687,690–F9–687,690間接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F8

The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

表 II 有 1 筆交易的價格引用這則附註。

F9

The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

表 II 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)